Open AccessOlaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
Author(s) -
Mark Yarchoan,
Melinda C. Myzak,
Burles A. Johnson,
Ana De Jesus-Acosta,
Dung T. Le,
Elizabeth M. Jaffee,
Nilofer S. Azad,
Ross C. Donehower,
Zheng Li,
Paul E. Oberstein,
Robert L. Fine,
Daniel A. Laheru,
Michael Goggins
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.17237
Subject(s) - olaparib , irinotecan , medicine , pancreatic cancer , cisplatin , mitomycin c , oncology , gemcitabine , camptothecin , cancer research , chemotherapy , cancer , surgery , poly adp ribose polymerase , colorectal cancer , biology , biochemistry , polymerase , gene
Olaparib is an oral inhibitor of polyadenosine 5'-diphosphoribose polymerization (PARP) that has previously shown signs of activity in patients with BRCA mutations and pancreatic ductal adenocarcinoma (PDAC).